113 related articles for article (PubMed ID: 33402593)
1. Lower pretreatment hemoglobin status and treatment breaks in locally advanced head and neck squamous cell carcinoma during concurrent chemoradiation.
Narayanasamy RK; Muthusekar RM; Nagalingam SP; Thyagarajan S; Ramakrishnan B; Perumal K
Indian J Cancer; 2021; 58(1):62-68. PubMed ID: 33402593
[TBL] [Abstract][Full Text] [Related]
2. Pre-radiotherapy Haemoglobin Level is A Prognosticator in Locally Advanced Head and Neck Cancers Treated with Concurrent Chemoradiation.
Narayanaswamy RK; Potharaju M; Vaidhyswaran AN; Perumal K
J Clin Diagn Res; 2015 Jun; 9(6):XC14-XC18. PubMed ID: 26266202
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Effects of Hemoglobin Levels Upon Tumor Response among Cervical Carcinoma Patients Undergoing Accelerated Hyperfractionated Radiotherapy versus Cisplatin Chemoradiotherapy.
Thakur P; Seam RK; Gupta MK; Rastogi M; Gupta M; Bhattacharyya T; Sharma M; Revannasiddaiah S
Asian Pac J Cancer Prev; 2015; 16(10):4285-9. PubMed ID: 26028087
[TBL] [Abstract][Full Text] [Related]
4. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
5. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
[TBL] [Abstract][Full Text] [Related]
6. Role of concomitant chemoradiation in locally advanced head and neck cancers.
Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Prosnitz RG; Yao B; Farrell CL; Clough R; Brizel DM
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1087-95. PubMed ID: 15752888
[TBL] [Abstract][Full Text] [Related]
8. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
Maguire PD; Neal CR; Hardy SM; Schreiber AM
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
[TBL] [Abstract][Full Text] [Related]
10. Baseline hemoglobin <11.0 g/dL has stronger prognostic value than anemia status in nasopharynx cancers treated with chemoradiotherapy.
Topkan E; Ekici NY; Ozdemir Y; Besen AA; Yildirim BA; Mertsoylu H; Sezen D; Selek U
Int J Biol Markers; 2019 Jun; 34(2):139-147. PubMed ID: 30864463
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
[TBL] [Abstract][Full Text] [Related]
12. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
13. Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer.
Zenda S; Hironaka S; Boku N; Yamazaki K; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Nishimura T
Dis Esophagus; 2008; 21(3):195-200. PubMed ID: 18430098
[TBL] [Abstract][Full Text] [Related]
14. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
Chang CL; Yuan KS; Wu SY
Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
[TBL] [Abstract][Full Text] [Related]
15. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS; Tao Y; Le Tourneau C; Pointreau Y; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Zubel A; Zanna C; Brienza S; Crompton P; Rouits E; Gollmer K; Szyldergemajn S; Bourhis J
Lancet Oncol; 2020 Sep; 21(9):1173-1187. PubMed ID: 32758455
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Rades D; Seibold ND; Gebhard MP; Noack F; Schild SE; Thorns C
Strahlenther Onkol; 2011 Oct; 187(10):626-32. PubMed ID: 21932027
[TBL] [Abstract][Full Text] [Related]
17. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis.
Helfenstein S; Riesterer O; Meier UR; Papachristofilou A; Kasenda B; Pless M; Rothschild SI
Radiat Oncol; 2019 Feb; 14(1):32. PubMed ID: 30744643
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
19. Low hemoglobin levels predict increased radiation-induced trismus rates in nasopharyngeal cancer.
Somay E; Yilmaz B; Topkan E; Pehlivan B; Selek U
Oral Dis; 2024 Apr; 30(3):1052-1060. PubMed ID: 37154238
[TBL] [Abstract][Full Text] [Related]
20. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94).
Ghadjar P; Pöttgen C; Joos D; Hayoz S; Baumann M; Bodis S; Budach W; Studer G; Stromberger C; Zimmermann F; Kaul D; Plasswilm L; Olze H; Bernier J; Wust P; Aebersold DM; Budach V
Strahlenther Onkol; 2016 Aug; 192(8):552-60. PubMed ID: 27323753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
